THE COMBINATION OF CDK4 AND MAPK/ERK PATHWAY INHIBITOR THERAPY IN MELANOMA: DEFINING MELANOMA CELL INTRINSIC AND IMMUNE MEDIATED RESPONSES

Grant number: 1100189 | Funding period: 2016 - 2019

Completed

Abstract

Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments do not induce long term disease control. Thus newer types of treatment are required to treat more advanced melanomas. Our proposal will use a drug that stops melanoma cells from growing and in combination with other drugs causes the cells to release factors that activate the immune system to eliminate the tumour.

Related publications (5)

Scholarly works icon

CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory

Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone

2021-10-01

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive brea..

Scholarly works icon

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma

Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard

2021-02-01

Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..

Scholarly works icon

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?

Lorey K Smith, Shaghayegh Arabi, Emily J Lelliott, Grant A McArthur, Karen E Sheppard

2020-06-01

Excess body weight has been identified as a risk factor for many types of cancers, and for the majority of cancers, it is associat..

Scholarly works icon

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

Emily J Lelliott, Carleen Cullinane, Claire A Martin, Rachael Walker, Kelly M Ramsbottom, Fernando Souza-Fonseca-Guimaraes, Shatha Abuhammad, Jessica Michie, Laura Kirby, Richard J Young, Alison Slater, Peter Lau, Katrina Meeth, Jane Oliaro, Nicole Haynes, Grant A McArthur, Karen E Sheppard

2019-02-04

Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor ..

Scholarly works icon

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance

Claire A Martin, Carleen Cullinane, Laura Kirby, Shatha Abuhammad, Emily J Lelliott, Kelly Waldeck, Richard J Young, Natalie Brajanovski, Donald P Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Richard B Pearson, Rodney J Hicks, Grant A McArthur, Karen E Sheppard

2018-05-15

Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are ..

University of Melbourne Researchers